HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
cilazaprilat
InChIKey: UVAUYSRYXACKSC-ULQDDVLXSA-N
Also Known As:
Ro 31-3113; Ro 313113; cilazaprilat anhydrous
Networked:
5
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyridazines: 11
Cilazapril: 287
cilazaprilat: 5
Experts
1.
Echizen, Hirotoshi
: 1 article (12/2014)
2.
Ogawa, Ryuichi
: 1 article (12/2014)
3.
Stachnik, Joan M
: 1 article (12/2014)
Related Diseases
1.
Hypoxia (Hypoxemia)
02/16/1999 - "
The present study was designed to examine whether an ACE inhibitor, cilazaprilat, directly protects cardiac myocytes against hypoxia/reoxygenation (H/R) injury.
"
02/16/1999 - "
Cilazaprilat significantly enhanced bradykinin production in the culture media of myocytes after 5.5 hours of hypoxia but not in that of nonmyocytes.
"
02/16/1999 - "
In addition, cilazaprilat markedly enhanced the cGMP content in myocytes during hypoxia, and this augmentation in cGMP could be blunted by L-NMMA and methylene blue but not by aminoguanidine.
"
2.
Coronary Occlusion
06/01/1998 - "
The ACE inhibitor cilazaprilat was administered into the coronary artery 10 minutes before coronary occlusion, and infusion was continued until 1 hour after reperfusion.
"
3.
Reperfusion Injury
12/01/1997 - "
Since a beneficial effect of ACE-inhibition on reperfusion injury has been reported, we investigated the impact of cilazaprilat on PMN dependent reperfusion injury in isolated guinea pig hearts.
"
4.
Ischemia
06/01/1998 - "
Although there were no significant differences in collateral flow during ischemia, infarct size in the cilazaprilat group was smaller than that in the control group (15.1+/-3.0% versus 46.7+/-4.2% of the area at risk, P<0.0001).
"
5.
Infarction (Infarctions)
06/01/1998 - "
Although there were no significant differences in collateral flow during ischemia, infarct size in the cilazaprilat group was smaller than that in the control group (15.1+/-3.0% versus 46.7+/-4.2% of the area at risk, P<0.0001).
"
06/01/1998 - "
The infarct size-limiting effect of cilazaprilat was partially reduced by either N(G)-nitro-L-arginine methyl ester (an inhibitor of NO synthase) or iberiotoxin (a blocker of Ca2+-activated K+ channels) and was abolished by N(G)-nitro-L-arginine methyl ester plus iberiotoxin.
"
Related Drugs and Biologics
1.
Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
2.
Enalaprilat (Vasotec)
3.
Bradykinin
4.
Calcium-Activated Potassium Channels (Calcium-Activated Potassium Channel)
5.
Perindopril
6.
Milrinone (Primacor)
7.
NG-Nitroarginine Methyl Ester (L-NAME)
8.
omega-N-Methylarginine (NG Monomethyl L Arginine)
9.
Nitric Oxide Synthase (NO Synthase)
10.
Enoximone
Related Therapies and Procedures
1.
Oral Administration